Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease

Journal of Clinical Immunology

Volumn 36, Issue 6, 2016, Pages 590-599

  Wasserman, Richard L ^a   Lumry, William ^b   Harris, James ^c   Levy, Robyn ^d   Stein, Mark ^e   Forbes, Lisa ^f   Cunningham Rundles, Charlotte ^g   Melamed, Isaac ^h   Kobayashi, Ai Lan ⁱ   Du, Wei ^j   Kobayashi, Roger ^k  

^a Allergy/Immunology Research Center of North Texas   (United States)

^b Allergy and Asthma Specialists   (United States)

^c LLP   (United States)

^d Family Allergy and Asthma Center PC   (United States)

^e Allergy Associates of the Palm Beaches   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h IMMUNOe International Research Centers   (United States)

ⁱ Midlands Hospital   (United States)

^j Clinical Statistics Consulting   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

clinical trial; efficacy; Intravenous immunoglobulin (IVIG); pharmacokinetics; primary immunodeficiency (PIDD); safety

Indexed keywords

ANTIBIOTIC AGENT; BACTERIUM ANTIBODY; CYTOMEGALOVIRUS ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B ANTIBODY; IMMUNOGLOBULIN; MEASLES ANTIBODY; NEUTRALIZING ANTIBODY; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RI 002; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ABSENTEEISM; ACUTE KIDNEY FAILURE; ACUTE SINUSITIS; ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; ASEPTIC MENINGITIS; BACTERIAL INFECTION; BRONCHITIS; CHILD; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; DIARRHEA; DRUG DISPOSITION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; ELIMINATION REACTION; EPISTAXIS; EXTRAVASATION; FATIGUE; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HEADACHE; HEMOLYSIS; HOSPITALIZATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; INFUSION RELATED REACTION; INJECTION SITE PAIN; INJECTION SITE REACTION; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MYALGIA; NAUSEA; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY VIRUS; RHINOPHARYNGITIS; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; SUBSTITUTION THERAPY; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSFUSION RELATED ACUTE LUNG INJURY; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; VOLUME OF DISTRIBUTION; X LINKED AGAMMAGLOBULINEMIA; CLINICAL TRIAL; COMPLICATION; DRUG MONITORING; IMMUNOLOGY; MIDDLE AGED; PNEUMOVIRUS; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84975322559     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-016-0308-z     Document Type: Article

References (30)

1. Boyle ML, Scalchunes C. Impact of intravenous immunoglobulin (IVIG) treatment among patients with primary immunodeficiency diseases. Pharm Policy Law. 2008;10:133–46.
2. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002;109(6):1001–4.
3. Cunningham-Rundles C, Maglione PJ. Common variable immunodeficiency. J Allergy Clin Immunol. 2012;129(5):1425–6. e3.
4. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and immunology. J Allergy Clin Immunol. 2006;117(4):S525–53.
5. Albin S, Cunningham-Rundles C. An update on the use of immunoglobulin for the treatment of immunodeficiency disorders. Immunotherapy. 2014;6(10):1113–26.
6. Quinti I. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31:315–22.
7. Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30.
8. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–60.
9. Berger M. Goals of therapy in antibody deficiency syndromes. J Allergy Clin Immunol. 1999;104:911–3.
10. Bonagura VR, Marchlewski R, Cox A, et al. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1):210–2.
11. Furst DE. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum. 2009;39(1):18–29.
12. Quartier P, Debré M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134(5):589–96.
13. Sastre P, Melero JA, Garcia-Barreno B, et al. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities. Vaccine. 2004;23(4):435–43.
14. Groothuis JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related illness II: immunoprophylaxis. Adv Ther. 2011;28(2):110–25.
15. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99(1):93–9.
16. Groothuis J. Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children. NEJM. 1993;329(21):1524–30.
17. American Academy of Pediatrics: Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102(5):1211–16.
18. FDA Guidance. Guidance for industry safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. June 2008.
19. Paes B, Manzoni P. Special populations: do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis? Early Hum Dev. 2011;87 Suppl 1:S55–8.
20. Faroux B. Insights from the Sixth Global Experts’ Meeting (GEM) on respiratory viruses: special populations. Paediatr Respir Rev. 2009;10 Suppl 1:21–2.
21. Simoes EA, Groothius JR, Tristram DA, et al. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr. 1996;129(2):214–9.
22. Boukhvalova MS. Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus. Bone Marrow Transplant. 2016;51(1):119–26.
23. Falsey AR. Polyclonal human intravenous immune globulin (IGIV) with high-levels of RSV neutralizing antibodies: a summary of animal and human studies. Annual Conference of the Canadian Blood and Marrow Transplant Group June 11–14, 2014.
24. Mond J. Treatment of normal and immune suppressed cotton rats with IVIG containing high neutralizing titer anti-RSV antibody. 9th International Respiratory Syncytial Virus Symposium November 2014.
25. Wasserman RL. A new intravenous immunoglobulin: bivigam for primary humoral immunodeficiency. Expert Rev Clin Immunol. 2014;10(3):325–37.
26. BIVIGAM Prescribing Information. 2013.
27. Orange JS, Du W, Falsey AR. Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses. Front Immunol. 2015;6:1–7.
28. Berger M, Pinciaro PJ, Althaus A, et al. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010;30:321–9.
29. Jolles S, Bernatowska E, de Garcia J, et al. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol. 2011;141:90–102.
30. Stein MR, Nelson RP, Church JA, et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29:137–44.